• Yevgen Mykhalchenko Zaporizhzhia State Medical University
  • Kateryna Aleksandrova Zaporizhzhia State Medical University
  • Oleksandr Shkoda Zaporizhzhia State Medical University
  • Yevgen Pruglo Zaporizhzhia State Medical University
Keywords: metabolic syndrome, xanthines, diuretic activity, hypoglycaemic activity


Aim – the search for biologically active compounds with diuretic and hypoglycemic action among 7-substituted of 3-benzyl-8-propylxanthines, which can be used for the treatment of pathologies of “metabolic syndrome”.

Materials and methods. 30 new chemical compounds among derivatives of 7-substituted of 3-benzyl-8-propylxanthines by PASS prediction filter were chosen for diuretic and hypoglycemic activity researches. Diuretic, hypoglycemic activity and for the most active compounds – the acute toxicity were studied in vivo. The molecular docking, which is based on EADock DSS mechanism of the modulation displayed the interaction between some of functional groups inside discovered xanthine ligands and known receptors and enzymes presented in Ligand-protein Database of Swiss Institute of Bioinformatics.

Results. It has been shown that synthesized compounds displayed strong diuretic and medium hypoglycemic activities. The molecular docking modulation (SwissDock) of interaction of xanthine derivatives hits with proposed receptors and enzymes revealed prospective of using 7-substituted of 3-benzyl-8-propylxanthines as potential drugs for treatment of metabolic syndrome pathologies.

Conclusion. The diuretic activity of the new 23 compounds of 7-substituted of 3-benzyl-8-propylxanthines and hypoglycemic activity of the new 7 derivatives of 7-substituted of 3-benzyl-8-propylxanthines was studied. Results of performed investigation illustrate that 7-substituted of 3-benzyl-8-propylxanthines demonstrate biological activity comparable to standard drugs. We also proposed probable molecular targets for the most active compounds by molecular docking method. It was shown that derivatives of 7-substituted of 3-benzyl-8-propylxanthines can be used for metabolic syndrome disorders prevention.


Download data is not yet available.

Author Biographies

Yevgen Mykhalchenko, Zaporizhzhia State Medical University

Department of Biological Chemistry

Kateryna Aleksandrova, Zaporizhzhia State Medical University

Department of Biological Chemistry

Oleksandr Shkoda, Zaporizhzhia State Medical University

Department of Biological Chemistry

Yevgen Pruglo, Zaporizhzhia State Medical University

Department of Clinical Pharmacy, Pharmacotherapy and MFE of FPE


Gharipour, M., Sadeghi, M., Hosseini, M., Andalib, E., Boroujeni, M. B., Sarrafzadegan, N. (2015) Effect of age on the phenotype of metabolic syndrome in developing country. Adv Biomed Res., 4, 103.

Grundy, S. M. (2016). Overnutrition, ectopic lipid and the metabolic syndrome. Journal of Investigative Medicine, 64 (6), 1082–1086. doi:

Saklayen, M. G. (2018). The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20 (2). doi:

National Diabetes Statistics Report (2017). Available at:

Clearfield, M., Pearce, M., Nibbe, Y., Crotty, D., Wagner, A. (2013). The “New Deadly Quartet” for Cardiovascular Disease in the 21st Century: Obesity, Metabolic Syndrome, Inflammation and Climate Change: How Does Statin Therapy Fit into this Equation? Current Atherosclerosis Reports, 16 (1). doi:

Vitaku, E., Smith, D. T., Njardarson, J. T. (2014). Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. Journal of Medicinal Chemistry, 57 (24), 10257–10274. doi:

Levich, S., Aleksandrova, K., Belenichev, I., Shkoda, A. (2013). Cerebroprotective activity of 3-benzylxanthine derivative – compound Ale-15, in conditions of bilateral common carotid arteries ligation (ischemic stroke). International Journal of Basic & Clinical Pharmacology, 2 (6), 705–710. doi:

Aleksandrova, K. V., Belenichev, I. F., Shkoda, O. S. (2016). Influence of 3-methylxanthine derivative on the morphological and functional characteristics of neurons of sensorimotor cortex of rats with experimental intracerebral hemorrhage. Journal of cerebral blood flow and metabolism, 36, 787.

Mikhal’chenko, E. K., Аleksandrova, K. V., Levich, S. V., Korzhova, A. S. (2017). Synthesis and physical-chemical properties of functional derivatives of 3-benzyl-8-propylxanthinyl-7-acetic acid. Current Issues in Pharmacy and Medicine: Science and Practice, 10 (2), 141–146. doi:

Aleksandrova, K. V., Mykhalchenko, Ye. K., Pruhlo, Ye. S., Sinchenko, D. M. (2018). Pat. No. 128510 UA. Hidrazyd 3-benzyl-8-propilksantyn-7-il atsetatnoi kysloty, yakyi vyiavliaie diuretychnu diiu. MPK: S07D 473/00. No u201802221 declareted: 05.03.2018; published: 25.09.2018, Bul. No. 18

Directive 2010/63/EU of the European Parliament and of the Council. (2016). Official Journal of the European Union.

Berkhin, Ye. B. (1977). Metody izucheniya deistviya novykh khimicheskikh soyedineniy na funkciyu pochek. Khimiko-farmatsevtychnyi zhurnal, 11 (5), 3–11.

Devi, K., Khanam, S., Rabbani, S. (2010). Protective role of glibenclamide against nicotinamide-streptozotocin induced nuclear damage in diabetic Wistar rats. Journal of Pharmacology and Pharmacotherapeutics, 1 (1), 18–23. doi:

Grosdidier, A., Zoete, V., Michielin, O. (2011). SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Research, 39, 270–277. doi:

Grosdidier, A., Zoete, V., Michielin, O. (2011). Fast docking using the CHARMM force field with EADock DSS. Journal of Computational Chemistry, 32 (10), 2149–2159. doi:

Klei, H. E. (2013). Crystal structure of dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP-IV-WT) complex with bms-767778 AKA 2-(3-(aminomethyl)-4-(2,4- dichlorophenyl)-2-methyl-5-oxo-5,7-dihydro-6h-pyrrolo[3,4- b]pyridin-6-yl)-n,n-dimethylacetamide. doi:

Loenze, P., Schimanski-Breves, S., Engel, C. K. (2012). Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Urea Inhibitor. doi:

Mueller, J. J., Schupp, M., Unger, T., Kintscher, U., Heinemann, U. (2011). Ligand binding domain of human ppar-gamma in complex with the agonist pioglitazone. doi:

Cheng, R. K. Y., Segala, E., Robertson, N., Deflorian, F., Dore, A. S., Errey, J. C. et. al. (2017). Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution. doi:

Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S., Morimoto, C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 261 (5120), 466–469. doi:

Marathe, C. S., Rayner, C. K., Jones, K. L., Horowitz, M. (2013). Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides, 44, 75–86. doi:

Meier, J. J., Nauck, M. A. (2005). Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews, 21 (2), 91–117. doi:

Hoehn, K., Marieb, E. N. (2010). Human Anatomy & Physiology. San Francisco: Benjamin Cummings.

Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J. et. al. (2006). International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 58 (4), 726–741. doi:

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002). Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA: The Journal of the American Medical Association, 288 (23), 2981–2997. doi:

Singh, N., Shreshtha, A. K., Thakur, M. S., Patra, S. (2018). Xanthine scaffold: scope and potential in drug development. Heliyon, 4 (10), e00829. doi:

👁 358
⬇ 242
How to Cite
Pharmacology, Toxicology and Pharmaceutical Science